Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults. Issue 12 (December 2016)

• Record Type: Journal Article
• Authors: Cressey, Tim R.; Hazra, Rohan; Wiznia, Andrew; Foca, Marc; Jean-Philippe, Patrick; Graham, Bobbie; King, Jennifer R.; Britto, Paula; Carey, Vincent J.; Acosta, Edward P.; Yogev, Ram
• Is Part Of: Pediatric infectious disease journal. Volume 35:Issue 12(2016)
• Publication Date: 2016-12
• Subjects: pharmacokinetics -- antiretrovirals -- atazanavir -- pediatrics; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000001320
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : HIV protease inhibitor use in pediatrics is challenging due to the poor palatability and/or toxicity of concomitant low-dose ritonavir. Atazanavir without ritonavir (unboosted) is not recommended for patients with prior virologic failure, a common problem for perinatally-infected adolescents. Atazanavir 400 mg once-daily provided suboptimal exposure. Higher unboosted doses or splitting the daily dose to twice-daily warrants investigation in this treatment-experienced population.